Product Pipeline

Product Pipeline

Edison Oncology Lead Programs

Our programs consist of biomarker-driven, small molecule, targeted drug candidates

EO-3001

ARID1a Targeted Therapy

Ovarian Clear Cell Cancer Carcinoma

& Solid Tumors

Pre-Clinical

0%

Phase 1-2 Clincal Trials 

0%

Registration Trial

0%

FDA Approval

0%
0%

EO-4426

Tezacitabine

Solid Tumors & Hematologic Malignancies

Pre-Clinical

0%

Phase 1-2 Clincal Trials 

0%

Registration Trial

0%

FDA Approval

0%
0%

OROTECAN®

(oral irinotecan HCI)

Pediatric Sarcomas

& Adult Malignancies

Pre-Clinical

0%

Phase 1-2 Clincal Trials 

0%

Registration Trial

0%

FDA Approval

0%
0%

Edison Oncology Partnered Programs

Apollomics licensed global rights (exChina/HK/Taiwan)​

EO-1001

Pan-ErbB inhibitor

Advanced/metastatic ErbB-positive solid tumors, including EGFR+, NSCLC, HER2+ breast cancer, glioblastoma, and others

Pre-Clinical

0%

Phase 1-2 Clincal Trials 

0%

Registration Trial

0%

FDA Approval

0%
0%

Our Pipeline – Lead Programs

Orotecan®:

Orotecan is a novel, patented oral formulation of irinotecan, a major cancer therapy.  Orotecan has been developed in collaboration with leading cancer clinicians to improve tolerability and patient compliance in the treatment of rare childhood tumors, with an opportunity to expand into major adult cancers.

EO3001 - mitochondrial targeting agent:

EO3001 was studied in prior clinical trials involving more than 1,000 cancer patients.  We have identified biomarker-circumscribed orphan cancer population that we believe will benefit from treatment with EO3001.  Edison Oncology has filed new patents related to these discoveries. 

EO1001:

Edison Oncology is planning clinical trials of EO-4426 in solid tumors and hematologic malignancies in 1H 2026.

Our Pipeline – Partner Programs

EO1001:

EO1001 is partnered with Apollomics Inc. EO1001 is a novel, irreversible pan-erbB inhibitor with excellent brain penetration offering the potential for improved efficacy for non-small cell lung cancer (NSCLC) and breast cancer patients with treatment-resistant disease, including brain metastasis. Edison Oncology has initiated the regulatory filing process and plans to initiate human clinical trials with EO1001 during 2021

Business Development Opportunities

Please contact us if you are interested in business opportunities.

;

Careers

Join our team! Visit our website to view available opportunities and apply now.

Investors

All prospective investors, please contact us if you are interested in learning more.